Genitourinary Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Genitourinary

Protocol SWOG S1802
Cancer Type: Metastatic Prostate Cancer
Fast Facts

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Protocol EA8171
Cancer Type: Prostate Cancer
Fast Facts

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

Protocol NRG GU009
Cancer Type: HIGH RISK PROSTATE CANCER
Fast Facts

PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

Protocol NRG GU010
Cancer Type: Prostate Cancer
Fast Facts

NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Protocol NRG GU011
Cancer Type: Prostate
Fast Facts

NRG-GU011, A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)

Protocol NRG GU013
Cancer Type: Prostate
Fast Facts

NRG-GU013, The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1931
Cancer Type: METASTATIC RENAL CELL CARCINOMA
Fast Facts

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

Protocol SWOG S2200
Cancer Type: Renal Cell
Fast Facts

SWOG - S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2).”

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031803
Cancer Type: BCG-Unresponsive Non Muscle Invasive Bladder
Fast Facts

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protocol SWOG S1937
Cancer Type: Metastatic Urothelial Carcinoma
Fast Facts

A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Please check out the rare protocol list to locate other studies within this disease site.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AREN03B2
Cancer Type: Renal-Biology
Fast Facts

Renal Tumors Classification, Biology, and Banking Study 

Patients must be < 30 Years Old at the Time of Diagnosis

Protocol COG AREN1921
Cancer Type: Wilms
Fast Facts

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.